ROLE OF ADJUVANT GAMMA-THERAPY IN THE TREATMENT OF RENAL CANCER

• Main Authors: F. R. Dzhabarov, A. N. Shevchenko, L. Ya. Rozenko
• Format: Article
• Language: Russian
• Published: ABV-press 2014-07-01
• Series: Onkourologiâ
• Subjects: renal cancer; adjuvant chemoradiotherapy; 5-year survival
• Online Access: https://oncourology.abvpress.ru/oncur/article/view/45

Data on 435 patients with pT1N0M0 renal cancer (RC) and grade (G)2-4 and pT1–4N0–2M0 RC and G1–4 were retrospectively analyzed. A control group (n = 212) underwent nephrectomy only; in a study group (n = 223), 5-fluorouracil 500 mg/m2 and leucovorin 200 mg/m2 were injected at a 5-hour interval before treatment and once a week at the stages of adjuvant gamma-teletherapy (GTT) with 1.2 Gy + 1.2 Gy to the bed of RC and to the area of lymph nodes. In the study group, five-year survival rates for pT1N0M cancer and G2–4 were 76.5 ± 5.4 % with a median of 58.2 ± 4.7 months; in the control group, these were 57.1 ± 6.6 % and 47.8 ± 2.4 months, respectively (p < 0.05). In pT1–4N0–2M0 and G1–4, without affecting the frequency of distant metastases, adjuvant chemoradiotherapy increased the survival in the first 2 follow-up years by 16 % (p < 0.05).